Best Heal Care Stocks To Own For 2014

A perfect storm is about to hit the gasoline market, making it possible that gas prices will jump by up to 20 cents per gallon over the next few days. With oil prices spiking and the onset of the peak driving season, drivers need to be prepared for some pain at the pump. Gasoline prices could be up to a nationwide average price of more than $3.70 per gallon, with some suggesting prices could reach an average of over $4 by the end of the summer.�

Photo Credit: Flickr

Oil prices, which typically make up about two-thirds of the price of gas, have been on the rise since the unrest in Egypt started heating up. In addition, output in neighboring Libya has been reduced, putting further pressure on world oil prices. Meanwhile, here in the U.S. our benchmark crude oil, West Texas intermediate, has risen to the point where it's within a few dollars of the global benchmark.�

Best Transportation Companies To Own For 2015: Bridgestone Corp (BRDCF)

BRIDGESTONE CORPORATION is a Japan-based manufacturing company mainly engaged in the tire related business. The Company has two business segments. The Tire segment is engaged in the manufacture and sale of tires and tubes for passenger automobiles, trucks, buses, construction and mine vehicles, industrial vehicles, agricultural machinery, aircrafts and motorcycles, as well as the provision of retread materials, tire-related products and raw materials. This segment also provides automotive maintenance and repair services. The Diversified Product segment provides automobile related parts, urethane foams, electronic precision parts, industrial material related products, construction related products, roofing materials, sports products, such as golf balls and golf clubs, bicycles, as well as financial services. As of December 31, 2012, the Company had 316 subsidiaries and 148 associated companies. Advisors' Opinion:

• [By MARKETWATCH]

  LOS ANGELES (MarketWatch) -- With the yen holding on to its gains and investors cautious as earnings season kicks off, Japanese stocks slid lower Friday after closing the previous day with some late-session gains. The Nikkei Stock Average (JP:NIK) fell 0.9% to 14,358.28, with the Topix down 0.8%, as the dollar bought 97.36 yen, little changed from 24 hours earlier. The relatively strong yen weighed on some names with high global exposure, as Sharp Corp. (JP:6753) (SHCAF) lost 1%, Pioneer Corp. (JP:6773) (PNCOF) dropped 1.6%, and Bridgestone Corp. (JP:5108) (BRDCF) fell 1.2%. An outlook cut from Canon Inc. (JP:7751) (CAJ) helped send its shares down 1%, while rival Nikon Corp. (JP:7731) (NINOF) lost 1.8%, though Olympus Corp. (JP:7733) (OCPNF) gained 1%. Telecoms were weak, with Softbank Corp. (JP:9984) (SFTBF) falling 2.5%, KDDI Corp. (JP:9433) (KDDIF) down 1.7%, and NTT DoCoMo Inc. (JP:9437) (NTDMF)

• [By WWW.MARKETWATCH.COM]

  LOS ANGELES (MarketWatch) -- Japan's Nikkei Average (JP:NIK) traded 0.5% higher in the early minutes Tuesday, extending the previous day's 0.9% advance, with the market getting some support from overnight gains for U.S. shares and a slightly weaker yen (dollar at 楼101.56 vs. 楼101.40 at Monday's open). Among the gainers, Toshiba Corp. (JP:6502) (TOSYY) rose 1.7%, Hitachi Ltd. (JP:6501) (HTHIF) gained 1.5%, NEC Corp. (JP:6701) (NIPNF) improved by 2.5%, Bridgestone Corp. (JP:5108) (BRDCF) added 2.7% to extend gains over the past couple weeks following the company's purchase of U.S.-based Masthead Industries, and Mitsubishi Heavy Industries Ltd. (JP:7011) (MHVYF) traded 1.1% higher as a Wall Street Journal report said the industrial major's Mitsubishi Aircraft unit had reached a tentative deal to sell 40 jets for the planned revival of defunct U.S. carrier Eastern Air Lines Group Inc. Auto makers were firmer as well, with Nissan Motor Co. (JP:7201) (NSANY) up 1.3%, Toyota Motor Corp. (JP:7203) (TM) up 0.5%, and Honda Motor Co. (JP:7267)

Best Heal Care Stocks To Own For 2014: Cell Therapeutics Inc (CTIC)

Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.

Pixuvri

As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.

OPAXIO

OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.

Tosedostat

In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.

Brostallicin

As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).

The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.

Advisors' Opinion:

• [By John Udovich]

  If you have not been watching the biotech sector lately, you should start paying attention as the sector along with small cap biotech stocks like Cell Therapeutics Inc (NASDAQ: CTIC), BIND Therapeutics Inc (NASDAQ: BIND) and TNI BioTech (OTCMKTS: TNIB) continue to produce a steady stream of good news for investors thanks to positive industry trends. Moreover, Ophthotech Corp (NASDAQ: OPHT), Foundation Medicine Inc (NASDAQ: FMI), Evoke Pharma and Fate Therapeutics Inc (NASDAQ: FATE) are this week's biotech IPOs that will no doubt be watched closely by Wall Street and industry observers in general. With that in mind, consider the following biotech news or recent articles about the industry and the small cap players in it:

• [By John Udovich]

  The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns�plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many�� planned biotech IPOs that have recently been announced publicly:

• [By Bryan Murphy]

  Like it or not, all good things must come to an end.... even for a red hot stock like Cell Therapeutics Inc. (NASDAQ:CTIC). Yes, CTIC is up 111% since the end of 2013, up 14% today alone, and it doesn't look like the bulls have any reason to slow down now. That's exactly why now's the time for current shareholders to be afraid, however - expect it when you least expect it.

Best Heal Care Stocks To Own For 2014: Reclaim Industries Ltd (RCM)

Reclaim Industries Limited is engaged in the manufacture of recycled rubber and its associated products. The principal activities of the Company include rubber recycling and manufacturing to convert used rubber tires into commercially surfacing, molded and granule products for a range of industries in both domestic and international markets. The Company operates in three segments: collections, manufacturing and sales. Collections, which is engaged in the pickup of tires from customers. Manufacturing, which is the processing of tires into rubber granule or baled tires. Sales, which is engaged in the laying of the rubber soft-fall surfaces or selling of rubber crumb and associated products to wholesale markets. Advisors' Opinion:

• [By Holly LaFon]

  Whitney George is Director of Investments, Managing Director, and a Portfolio Manager of Royce & Associates, LLC, investment advisor to The Royce Funds. He serves as portfolio manager for Royce Premier Fund (RPR), Royce Low-Priced Stock Fund (RLP), Royce Global Value Fund (RGV), Royce SMid-Cap Value Fund (RSV), and Royce Focus Trust (FUND). He also serves as assistant portfolio manager for Royce Micro-Cap Fund (RMC), Royce Value Fund (RVV), Royce Value Plus Fund (RVP), Royce Focus Value Fund (RFV), and Royce Capital Fund ��Micro-Cap Portfolio (RCM). Mr. George's thoughts in this interview concerning the stock market are solely his own and, of course, there can be no assurance with regard to future market movements.

Best Heal Care Stocks To Own For 2014: WD-40 Co (WDFC)

WD-40 Company incorporated on October 22, 1999, is a global consumer products company dedicated to delivering solutions for a range of maintenance needs of doer and on-the-job users. As of August 31, 2012, the Company�� products included WD-40 Smart Straw, WD-40 Trigger Pro, 3-IN-ONE Professional Garage Door Lube, Spot Shot Pet Clean which is a non-aerosol Spot Shot trigger product, Blue Works product line, and a mildew stain remover under the X-14 brand. In addition, its WD-40 Speciality product line, consists of certain specialty maintenance products. The Company�� three geographical segments are: the Americas, Europe and Asia-Pacific. The Company sells its products primarily through mass retail and home center stores, warehouse club stores, grocery stores, hardware stores, automotive parts outlets and industrial distributors and suppliers. During the fiscal year ended August 31, 2012, the Company formed WD-40 Bike Company LLC, focused on the development of a line of bicycle maintenance products for cyclists and mechanics.

Multi-Purpose Maintenance Products

The WD-40 brand is a multi-purpose maintenance product and is sold as an aerosol spray, a non-aerosol trigger spray and in liquid form through mass retail stores, hardware stores, warehouse club stores, automotive parts outlets and industrial distributors and suppliers. WD-40 products are sold worldwide in markets, such as North, Central and South America, Asia, Australia and the Pacific Rim, Europe, the Middle East and Africa. WD-40 products has a range of consumer uses in household, marine, automotive, construction, repair, sporting goods and gardening applications, in addition to numerous industrial applications. The 3-IN-ONE brand consists of multi-purpose drip oil and spray lubricant products, as well as other specialty maintenance products. The drip oil is an entry-level lubricant with spout options that allow applications for small mechanisms and assemblies, tool maintenance and threads on screws and bolts. It! also has industrial applications in areas, such as locksmithing, heating, ventilation, and air conditioning (HVAC), marine, farming, construction and jewelry manufacturing. In addition to the drip oil line of products, the 3-IN-ONE brand also includes a line of products known as 3-IN-ONE Professional, which is a line of multi-purpose maintenance products. 3-IN-ONE products are sold in the United States, Europe, Canada, Latin America, Australia and Asia.

The Blue Works brand consists of a line of industrial grade, specialty maintenance products that include lubricants, penetrants, degreasers and cleaners designed specifically for the needs of industrial users. Blue Works products were launched in the United States in selected markets in Europe and are sold through the industrial channel. WD-40 Specialist consists of a line of specialty problem solving products that include penetrants, water resistant silicone sprays, corrosion inhibitors and rust removers that are aimed at the current users of the WD-40 brand.

Homecare and Cleaning Products

The X-14 brand is a line of products designed for cleaning needs. X-14 is sold as a liquid mildew stain remover and two types of automatic toilet bowl cleaners. X-14 is sold in the United States through grocery and mass retail channels. The 2000 Flushes brand is a line of long-lasting automatic toilet bowl cleaners, which includes a variety of formulas. 2000 Flushes is sold in the United States and Canada through grocery and mass retail channels. The Carpet Fresh brand is a line of room and rug deodorizers sold as powder, aerosol foam and trigger spray products. Carpet Fresh is sold through grocery and mass retail channels in the United States, United Kingdom and Australia. In the United Kingdom, Carpet Fresh is sold under the 1001 brand name. In Australia, Carpet Fresh is sold under the No Vac brand name.

The Spot Shot brand is sold as an aerosol carpet stain remover and a liquid trigger carpet stain and odor e! liminator! . The brand also includes products, such as Spot Shot Instant Carpet Stain & Odor Eliminator and Spot Shot Pet Clean, which are non-toxic and biodegradable. Spot Shot products are sold through grocery and mass retail channels, warehouse club stores and hardware and home center stores in the United States and Canada. Spot Shot products are also sold in the United Kingdom under the 1001 brand name. The 1001 brand includes carpet and household cleaners and rug and room deodorizers, which are sold through mass retail, grocery and home center stores in the United Kingdom. The Lava and Solvol brands consist of heavy-duty hand cleaner products, which are sold in bar soap and liquid form through hardware, grocery, industrial, automotive and mass retail channels. Lava is sold in the United States, while Solvol is sold in Australia.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on WD-40 (Nasdaq: WDFC  ) , whose recent revenue and earnings are plotted below.

• [By Marc Bastow]

  On-the-job maintenance services products manufacturer WD-40 (WDFC) raised its quarterly dividend 10% to 34 cents per share, payable on Jan. 31 to shareholders of record as of Jan. 6.
  WDFC Dividend Yield: 1.82%

• [By Steve Symington]

  On Tuesday, shares of WD-40�Company (NASDAQ: WDFC  ) rose by as much as 12% before giving back all of those gains�to trade flat by the end of the session.

• [By WWW.DAILYFINANCE.COM]

  Murray Close, Warner Bros./AP From a major banking institution kicking off the new earnings season to the most-anticipated theme park debut of the year staging its grand opening, here are some things that will help shape the week that lies ahead on Wall Street. Monday -- Food for Thought The market's going to get off to a slow start on the news front. That's not a surprise given that it was closed Friday for Independence Day. One company that will be in the news on Monday is food and industrial products maker Penford (PENX). Penford's wide range of products include food ingredients, pet and animal products, sustainable bioproducts, starches for paper and packaging products and biofuels. Analysts see Penford earning 21 cents a share, but keep in mind that it has come up short against Wall Street expectations in each of the three previous quarters. Tuesday -- Harry Potter Central Florida will be a bit busier than usual on Tuesday when Comcast's (CMCSK) Universal Orlando has its grand opening of the new Diagon Alley expansion to The Wizarding World of Harry Potter. It's been a rough start. July 8 wasn't the opening date that the park originally wanted, judging by the fact that it had "The Tonight Show" and "Today" run weeklong tie-ins a few weeks ago. Conveniently for Comcast, it owns both the Universal theme parks and NBC. However, with the expansion's indoor coaster proving unreliable -- and even Universal pass holders being denied early access to attractions outside of the new Hogwarts Express train ride -- it could be an interesting debut. The crowds should be huge, the expectations lofty. Wednesday -- Mopping Up WD-40 (WDFC) reports on Wednesday afternoon. This is the company behind the multi-use lubricant. It also offers industrial cleaners, toilet sanitizers and other compounds. WD-40 didn't work out for its shareholders last time out. It posted better than expected 9 percent growth in revenue, but earnings fell just short of expectations. WD-4

Best Heal Care Stocks To Own For 2014: APM Automotive Holdings Bhd (APM)

APM Automotive Holdings Berhad is a Malaysia-based investment holding company. The Company operates in six divisions: Suspension Division, which includes products, such as leaf springs, parabolic springs, coil springs, shock absorbers, gas springs, U-bolts and metal parts; Interior & Plastics Division, which includes products, such as plastics parts, interiors, seatings for motor vehicles, buses, auditoriums and cinemas; Electrical & Heat Exchange Division, which includes products, such as air-conditioning systems, radiators, starter motors, alternators, wiper system, distributors and other electrical parts; Marketing Division, which includes trading and distribution of automotive components/parts manufactured by it for the replacement and export market; Others, which include operations related to the rental of investment properties in Malaysia, and Operations Outside Malaysia include businesses in Indonesia, Vietnam, Australia and United States. Advisors' Opinion:

• [By Damian Illia]

  Since 1973 Compuware Corp (CPWR) has been providing software solutions both on-premise and through a software as a service (SaaS) model, as well as professional technical services related to mobile application developments and mainframe systems. The company reported revenues of $944.5 million in fiscal 2013, working through four segments: Performance Management (APM), Mainframe, Changepoint and Uniface. Through the APM segment Compuware provides services to maximize efficiency of web, non-web, mobile, streaming and cloud applications. Mainframe solutions are designed for organizations which require high developer productivity and enhanced service quality at lower costs, and through Changepoint it provides Professional Services Automation (PSA) and Project Portfolio Management services (PPM). Uniface, a rapid application development platform, creates renews and integrates enterprise applications. Currently, more than 7,100 companies, including many of the world's largest organizations, depend on Compuware and our new generation approach to performance management to do just that.

Best Heal Care Stocks To Own For 2014: Basilea Pharmaceutica AG (BSLN)

Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant bacterial infections, systemic fungal infections and drug-resistant tumors. The Company�� anti-infectives, including isavuconazole and ceftobiprole are in late-stage clinical development, while the novel antibiotic, BAL30072 and the oncology compound, BAL101553 are in clinical phase I. The Company�� subsidiaries include Basilea Pharmaceutica China Ltd., Basilea Pharmaceuticals A/S, Basilea Pharma SAS, Basilea Pharmaceutica Deutschland GmbH, Basilea Pharmaceutica International Ltd., BPh Investitionen Ltd., Basilea Medical Ltd. and Basilea Pharmaceuticals Ltd. Advisors' Opinion:

• [By Corinne Gretler]

  Basilea Pharmaceutica AG (BSLN) increased 2.1 percent to 107.10 francs. The Swiss drug developer said the U.S. Food and Drug Administration granted orphan-drug designation to its isavuconazole for the treatment of zygomycosis, a life-threatening fungal infection.